Sandoz Group shareholders walked into this earnings day with a stock that had inched higher over the past week but gone essentially sideways over the past month. The market is still trying to decide whether a rich P/E of 57.2x belongs on a generics and biosimilars specialist or on a high growth story that just happens to sell off patent drugs.
H1 2026 results gave that debate fresh fuel. Net sales reached about US$5.8b with a core earnings before interest, tax, depreciation and amortisation margin of 20.9%. Net profit margin stands at 5.5%. The emotional tug of a high valuation now sits directly against a cleaner, more profitable business story.
Is Sandoz Group’s 57.2x P/E a sign the market is overpaying for a slow top line, or a rational price for a sharp earnings rebound and margin lift? Compare that story with our valuation analysis for Sandoz Group
H1 2026 Earnings Summary
- Revenue H1 2026 vs. H1 2025: US$5,892m vs. US$5,322m (up about 10.7%)
- Net Income H1 2026 vs. H1 2025: US$537m vs. a loss of US$150m (a substantial year-over-year shift back to profit)
- Basic EPS H1 2026 vs. H1 2025: US$1.24 vs. a loss of US$0.35 per share (a significant improvement back into positive territory)
- Core EBITDA Margin H1 2026 vs. H1 2025: 20.9% vs. about 20.0% (an increase of 0.9 percentage points)
Prefer clean charts over another wall of earnings figures and margin percentages? Get a full visual view of Sandoz Group, including how its valuation compares with its recent earnings rebound, in the company report for Sandoz Group.
Sandoz Bull Case: Biosimilars And Margins Get Real-World Tests
Bulls argue Sandoz can turn a biosimilars heavy pipeline and in-house manufacturing into both faster growth and structurally higher margins. H1 gives concrete progress against that script. Net sales grew mid single digit while core EBITDA rose around 15%, and the core EBITDA margin reached 20.9%, close to the full year target of about +100bp improvement. That points to early traction from efficiency and scale, not just volume.
The bolder part of the narrative is that biosimilars become the clear engine of the group. Here Sandoz hits visible milestones. Biosimilar sales grew about 20% and now represent 33% of net sales, with rapid uptake in Wyost, Jubbonti and Pyzchiva and strong GLP 1 diabetes positioning through semaglutide in Brazil. Generics look steadier after Q1 issues, which helps the story of a cleaner base business supporting the biosimilar push.
Reveal where the surface looks calm but the multi year models start to diverge for Sandoz Group, and see what the street is quietly baking in for the next few years through the analyst estimates for Sandoz Group.Sandoz Bear Case: Pricing Squeeze And Heavy Spend Still Bite
The bearish view on Sandoz Group focuses on two points: drug pricing pressure that erodes earnings quality, and heavy fixed investment that leaves margins exposed. H1 results only partly ease those worries. Net sales and core EBITDA are moving in the right direction, yet management still talks about pricing declines and cites German pressure even in strong biosimilar brands like Pyzchiva. That supports the idea that volume is doing more of the work than price.
The second concern is that elevated CapEx and litigation could weigh on cash and keep reported earnings messy. CapEx is set to peak around US$1.1b in 2026, and one offs are guided at roughly US$300m for the year. Free cash flow of about US$503m in H1 is solid, but not enough to dismiss concerns that returns on this investment cycle are unproven, while regulatory and launch risks for key GLP 1 and biosimilar assets remain live.
With Sandoz Group committing about US$1.1b of CapEx and roughly US$300m of one offs in 2026, can current free cash flow and balance sheet strength really support this spending without pressure on future options? Check the financial health analysis of Sandoz Group stock.Stay Ahead With Simply Wall St
If Sandoz Group’s high P/E and the recent swing back into profit have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and spot a potential entry that fits your plan. After you own the stock, keep your decisions grounded in data by using the Portfolio Command Center to cut through noise and surface only the most important updates on earnings, cash flows and valuation. For a longer term view, use the Community to see how other investors are thinking about Sandoz Group and which risks or catalysts they are watching. This is how you uncover key shifts early and stay a step ahead of the market.
Seeking Alternatives Beyond Sandoz Group?
Fresh ideas move first when momentum starts breaking out and quiet stories stop flying under the radar. Scan what others miss before the crowd catches up and act now.
- Spot potential breakout income plays by reviewing 439 dividend fortresses to keep cash returns front and center while prices are still catching up.
- Chase possible future growth stories early by scanning 548 high quality undiscovered gems that remain under the radar for now but may not stay quiet forever.
- Focus on staying power by checking the list of solid balance sheet and fundamentals stocks (422 results) before strong balance sheets are fully reflected by later movers.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com